Targeting the Androgen Receptor in Breast Cancer

Sara Hurvitz, MD, discusses recent updates for selective estrogen receptor degraders in the treatment of patients with metastatic breast cancer and how it has impacted clinical decisions.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed adverse event management in patients treated with sacituzumab govitecan for triple-negative breast cancer and other therapy options. This is the second of 2 articles based on this event.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

With a broadened FDA label for abemaciclib, patients high-risk breast cancer can now be categorized based only on nodal status, tumor size, and tumor grade.

Miguel Pelayo, MD, discusses what he sees as practice-changing treatments for patients with triple-negative breast cancer and how he helps patients feel confident in these new treatments.